Citadel Advisors
RNAC icon

Citadel Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Citadel Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,000
Closed -$164K – 13856
2025
Q3 		$164K Buy
16,000
+2,700
+20% +$30.3K ﹤0.01% 11462
2025
Q2 		$138K Buy
+13,300
New +$142K ﹤0.01% 11039
2024
Q2 		– Sell
-560
Closed -$10.9K – 15213
2024
Q1 		$10.9K Buy
560
+553
+7,900% +$11.7K ﹤0.01% 13438
2023
Q4 		$138 Sell
7
-516
-99% -$15.4K ﹤0.01% 14116
2023
Q3 		$16.6K Sell
523
-200
-28% -$6.68K ﹤0.01% 12768
2023
Q2 		$24.3K Sell
723
-557
-44% -$19.9K ﹤0.01% 12562
2023
Q1 		$53.4K Buy
1,280
+743
+138% +$34.9K ﹤0.01% 12071
2022
Q4 		$18.2K Sell
537
-466
-46% -$19.8K ﹤0.01% 13213
2022
Q3 		$49K Buy
1,003
+570
+132% +$31.3K ﹤0.01% 11652
2022
Q2 		$17K Buy
433
+76
+21% +$2.25K ﹤0.01% 12461
2022
Q1 		$13K Sell
357
-383
-52% -$24K ﹤0.01% 13346
2021
Q4 		$72K Sell
740
-2,637
-78% -$284K ﹤0.01% 13013
2021
Q3 		$421K Sell
3,377
-940
-22% -$114K ﹤0.01% 10289
2021
Q2 		$541K Sell
4,317
-6,033
-58% -$718K ﹤0.01% 9898
2021
Q1 		$1.41M Buy
+10,350
New +$1.28M ﹤0.01% 7269
2020
Q4 		– Sell
-1,580
Closed -$118K – 11430
2020
Q3 		$118K Buy
+1,580
New +$121K ﹤0.01% 9172

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's RNAC Position: Q1 2026 in Review

Citadel Advisors increased its Cartesian Therapeutics (RNAC) stake by 38% in Q1 2026, buying an estimated $216K and bringing the position to 110,128 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #8565.

Citadel Advisors first reported a position in RNAC in Q4 2018 and has held it in 24 quarters since. The position peaked at $5.76M in Q3 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Citadel Advisors held 110,128 shares of Cartesian Therapeutics worth $677K as of Q1 2026.
  • Citadel Advisors bought 30,343 Cartesian Therapeutics shares in Q1 2026, an estimated $216K.
  • Cartesian Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8565 holding.
  • Citadel Advisors first reported a position in Cartesian Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • Citadel Advisors's Cartesian Therapeutics position peaked at $5.76M in Q3 2024.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.